Price (delayed)
$2.42
Market cap
$368.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.09
Enterprise value
$520.6M
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...
Highlights
Heron Therapeutics's EPS has surged by 89% YoY and by 44% QoQ
Heron Therapeutics's net income has soared by 88% YoY and by 51% from the previous quarter
The quick ratio has contracted by 14% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of HRTX
MarketValuationsEarnings
Shares outstanding
152.33M
Market cap
$368.64M
Enterprise value
$520.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.61
Revenue
$144.29M
Gross profit
$105.64M
Operating income
-$11.53M
Net income
-$13.58M
EBIT
-$11.1M
EBITDA
-$8.61M
Free cash flow
-$24.21M
Per shareBalance sheetLiquidity
EPS
-$0.09
EPS diluted
-$0.09
Free cash flow per share
-$0.16
Book value per share
-$0.22
Revenue per share
$0.95
TBVPS
$1.53
Total assets
$233.15M
Total liabilities
$266.8M
Debt
$177.76M
Equity
-$33.65M
Working capital
$117.56M
Debt to equity
-5.28
Current ratio
2.29
Quick ratio
1.51
Net debt/EBITDA
-17.66
MarginsEfficiencyDividend
EBITDA margin
-6%
Gross margin
73.2%
Net margin
-9.4%
Operating margin
-8%
Return on assets
-6.1%
Return on equity
N/A
Return on invested capital
-3.8%
Return on capital employed
-7.8%
Return on sales
-7.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRTX stock price
How has the Heron Therapeutics stock price performed over time
Intraday
3.42%
1 week
10%
1 month
7.08%
1 year
4.31%
YTD
58.17%
QTD
10%
Financial performance
How have Heron Therapeutics's revenue and profit performed over time
Revenue
$144.29M
Gross profit
$105.64M
Operating income
-$11.53M
Net income
-$13.58M
Gross margin
73.2%
Net margin
-9.4%
HRTX financials
HRTX's operating margin has surged by 91% year-on-year and by 57% since the previous quarter
The operating income has surged by 90% year-on-year and by 56% since the previous quarter
The net margin has soared by 89% year-on-year and by 54% since the previous quarter
Heron Therapeutics's net income has soared by 88% YoY and by 51% from the previous quarter
Growth
What is Heron Therapeutics's growth rate over time
HRTX growth chart
Valuation
What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.61
Price to earnings (P/E)
Heron Therapeutics's EPS has surged by 89% YoY and by 44% QoQ
Price to book (P/B)
The equity is up by 16% since the previous quarter
Price to sales (P/S)
HRTX's price to sales (P/S) is 65% less than its 5-year quarterly average of 7.3 and 5% less than its last 4 quarters average of 2.7
HRTX's revenue is up by 14% year-on-year and by 4.8% since the previous quarter
Efficiency
How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has surged by 91% YoY and by 61% QoQ
The ROIC has soared by 90% YoY and by 59% from the previous quarter
HRTX's ROA has soared by 88% YoY and by 52% QoQ
Dividends
What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRTX.
Financial health
How did Heron Therapeutics financials performed over time
Assets vs liabilities
Heron Therapeutics's total assets is 13% lower than its total liabilities
The quick ratio has contracted by 14% YoY and by 6% from the previous quarter
Heron Therapeutics's total assets has increased by 6% QoQ and by 4.8% YoY
Debt vs equity
The debt to equity has declined by 18% since the previous quarter
The equity is up by 16% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.